Sphingosylphosphorylcholine 

Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a K_d of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes^{[1][2][3][4][5][6][7]}.

Sphingosylphosphorylcholine (10 nM-50 μM; 24 h post-transfection incubation) activates TRPM3 in HEK293T cells to induce intracellular calcium elevation primarily via extracellular calcium influx, with a minor contribution from endoplasmic reticulum calcium stores, and this activation is independent of Gβγ signaling^[2].
Sphingosylphosphorylcholine (15-20 μM; 15 min-4 h) potently induces actin stress fiber formation and focal adhesion assembly in mouse ES cell-derived EB outgrowths in a concentration- and time-dependent manner^[3].
Sphingosylphosphorylcholine (10 μM) inhibits Ang II-induced hypertrophy in neonatal mouse cardiomyocytes, reducing cell surface area and lowering ANP and BNP protein levels^[4].
Sphingosylphosphorylcholine (10 μM; 210 min hypoxia, 150 min reoxygenation) protects rat neonatal cardiomyocytes from apoptosis induced by 210 min of hypoxia followed by 150 min of reoxygenation^[5].
Sphingosylphosphorylcholine (0.5-100 nM; 0-140 min) binds to OGR1 in OGR1-transfected HEK293 cells with high affinity (K_d = 33.3 nM) and high specificity^[6].
Sphingosylphosphorylcholine (0.1-5 μM; 24 h) upregulates cell surface expression of uPA and its receptor uPA-R in normal human foreskin keratinocytes in a dose-dependent manner over 24 h^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sphingosylphosphorylcholine (100 nmol per site; intradermal injection) induces significant scratching behavior in *Mus musculus* without triggering pain-related wiping behavior, which confirms its pruritic activity^[2].
Sphingosylphosphorylcholine (10 μM/kg/day; subcutaneous injection; daily, for 4 consecutive weeks) increases the survival rate of mice to 63%, and alleviates pressure overload-induced myocardial hypertrophy, fibrosis and apoptosis by inhibiting the CaM-JNK/p38 signaling pathway^[4].
Sphingosylphosphorylcholine (0.625-2.5 μg/g body weight; intravenous injection; prophylactic administration 30 minutes before coronary artery ligation, or administration at the onset of reperfusion) dose-dependently reduces myocardial infarct size via a mechanism dependent on the S1P₃ receptor: the reduction reaches up to 50% with prophylactic administration and 40% with administration upon reperfusion^[5].
Topical application of 2 μM Sphingosylphosphorylcholine statistically significantly promotes skin wound healing in diabetic db/db mice with genetically impaired healing capacity, as evidenced by reduced wound area, increased granulation tissue volume, and shortened length of non-re-epithelialized wound surface^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

464.62

C₂₃H₄₉N₂O₅P

1670-26-4

Solid

White to off-white

CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)COP(OCC[N+](C)(C)C)([O-])=O

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Jeon ES, et al. Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism. J Cell Sci. 2006;119(Pt 23):4994-5005.  [Content Brief]

  [2]. Song DE, et al. Sphingosylphosphorylcholine induces itch via activation of TRPM3 and TRPA1 in mice. Biochem Pharmacol. 2025;237:116952.  [Content Brief]

  [3]. Kleger A, et al. The bioactive lipid sphingosylphosphorylcholine induces differentiation of mouse embryonic stem cells and human promyelocytic leukaemia cells. Cell Signal. 2007;19(2):367-377.  [Content Brief]

  [4]. Ren FF, et al. Sphingosylphosphorylcholine alleviates pressure overload-induced myocardial remodeling in mice via inhibiting CaM-JNK/p38 signaling pathway. Acta Pharmacol Sin. 2024;45(2):312-326.  [Content Brief]

  [5]. Herzog C, et al. Intravenous sphingosylphosphorylcholine protects ischemic and postischemic myocardial tissue in a mouse model of myocardial ischemia/reperfusion injury. Mediators Inflamm. 2010;2010:425191.  [Content Brief]

  [6]. Xu Y, et al. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol. 2000 May;2(5):261-7. doi: 10.1038/35010529. Retraction in: Nat Cell Biol. 2006 Mar;8(3):299.  [Content Brief]

  [7]. Wakita H, et al. Sphingosylphosphorylcholine stimulates proliferation and upregulates cell surface-associated plasminogen activator activity in cultured human keratinocytes. J Invest Dermatol. 1998;110(3):253-258.  [Content Brief]